Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) is -78.78% lower on its value in year-to-date trading and has touched a low of $0.59 and a high of $8.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IRWD stock was last observed hovering at around $0.97 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $0.94, the stock is -4.25% and -29.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.31 million and changing -3.12% at the moment leaves the stock -73.69% off its SMA200. IRWD registered -88.36% loss for a year compared to 6-month loss of -76.38%. The firm has a 50-day simple moving average (SMA 50) of $1.3408 and a 200-day simple moving average (SMA200) of $3.5738.
The stock witnessed a -33.32% gain in the last 1 month and extending the period to 3 months gives it a -75.26%, and is 30.69% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.23% over the week and 13.71% over the month.
Ironwood Pharmaceuticals Inc (IRWD) has around 253 employees, a market worth around $152.13M and $351.41M in sales. Current P/E ratio is 87.06 and Fwd P/E is 2.51. Profit margin for the company is 0.52%. Distance from 52-week low is 59.09% and -88.87% from its 52-week high. The company has generated returns on investments over the last 12 months (0.61%).
The EPS is expected to grow by 844.75% this year.
Ironwood Pharmaceuticals Inc (IRWD) Top Institutional Holders
298.0 institutions hold shares in Ironwood Pharmaceuticals Inc (IRWD), with institutional investors hold 103.75% of the company’s shares. The shares outstanding are 160.21M, and float is at 156.66M with Short Float at 7.43%. Institutions hold 101.74% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.88 million shares valued at $149.16 million. The investor’s holdings represent 14.3868% of the IRWD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 21.56 million shares valued at $140.59 million to account for 13.5607 of the shares outstanding. The other top investors are SARISSA CAPITAL MANAGEMENT LP which holds 16.39 million shares representing 10.3073% and valued at over $106.86 million, while UBS GROUP AG holds 7.1023 of the shares totaling 11.2 million with a market value of $73.03 million.
Ironwood Pharmaceuticals Inc (IRWD) Insider Activity
The most recent transaction is an insider sale by MCCOURT Thomas A, the company’s Chief Executive Officer. SEC filings show that MCCOURT Thomas A sold 139,064 shares of the company’s common stock on Feb 10 ’25 at a price of $1.76 per share for a total of $0.24 million. Following the sale, the insider now owns 1.16 million shares.
Ironwood Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 10 ’25 that Silver Ronald (Principal Accounting Officer) sold a total of 12,048 shares of the company’s common stock. The trade occurred on Feb 10 ’25 and was made at $1.76 per share for $21204.0. Following the transaction, the insider now directly holds 0.28 million shares of the IRWD stock.
Still, SEC filings show that on Feb 10 ’25, Shetzline Michael (SVP, CMO, Head-Res&Drug) disposed off 41,269 shares at an average price of $1.76 for $72633.0. The insider now directly holds 554,007 shares of Ironwood Pharmaceuticals Inc (IRWD).
